Debunking the Myths of Treating Hepatitis C

08.05.14 | By

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)

Medicare Part D Continues to Be A Success

08.04.14 | By

Medicare Part D continues to be a success for beneficiaries.

Week in Review: The Age-Old Tale of Cost & Value

08.01.14 | By

This week was packed with lively and informative discussions surrounding the incredibly important issue of treatment costs and the need to incorporate value into the cost narrative.

Modi’s New Era Has Begun

07.31.14 | By

Following up on our May post, the next chapter in the rebuilding of the U.S. – India relationship has begun, as U.S. Secretary of State John Kerry and Secretary of Commerce Penny Pritzker are in India to meet with their counterparts in the new Indian government. Secretary Kerry will partake in the fifth U.S.-India Strategic Dialogue and also meet with Prime Minister Modi, the first meetings to occur between high-ranking officials from the U.S. and India since Modi’s election in May.

Weighing-in on the Cost and Value of Innovation

07.31.14 | By

Earlier this week, PhRMA participated in the Wall Street Journal’s first tweet chat hosted by Ed Silverman, who spearheads the publication’s blog, Pharmalot.

World Hepatitis Day: Driving Momentum to Help Patients

07.29.14 | By

For the millions of patients battling hepatitis C, World Hepatitis Day will hopefully be a day that is only read about in history books.

Now, more than ever before, there is great hope on the horizon as new and forthcoming medicines can provide nearly all patients fighting this disease with a cure. 

Assessing the Long-Term Value of Hepatitis C Treatments

07.25.14 | By

The current debate regarding the cost of new and forthcoming hepatitis C treatments has brought to light a long-standing discussion about the cost and value of innovative new medicines.

Energy and Commerce Health Subcommittee Explores Need for More Robust Communication about Real World Uses of Medicines

07.25.14 | By

As part of the 21st Century Cures initiative, the House Energy and Commerce Subcommittee on Health discussed barriers to evidence development and communication for medicines and devices.

Breakthrough Genetic Findings and Historic Donation Spur Mental Health Research

07.25.14 | By

Mental health conditions affect 1 in 4 Americans and take a heavy economic toll on the United States. Efforts to find effective treatments for conditions such as anxiety, depression, schizophrenia and substance abuse disorders continue despite difficult hurdles and setbacks.

Funding to Help the Bridge Science

07.22.14 | By

Pharmacology is often described as a bridge science because it incorporates knowledge and skills from a number of basic science disciplines including physiology, biochemistry and cell and molecular biology. Pharmacologists are able to 'translate' such knowledge into the rational development of therapeutics. As a result of their multidisciplinary training, pharmacologists are able to offer a unique perspective in solving drug-, hormone- and chemical-related problems.

Pages

Subscribe to RSS - Opinion